Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
复制标题
DOI：
10.1016/s2666-5247(21)00305-0
复制
发表时间：
2022-04
期刊：
影响因子：
--
通讯作者：
Uluçkan Ö
中科院分区：
文献类型：
--
作者：
Barin B;Kasap U;Selçuk F;Volkan E;Uluçkan Ö
接种疫苗是控制COVID-19疫情的有效策略。在北塞浦路斯，疫苗分发首先是CoronaVac，其次是BNT 162 b2和ChAdOx 1疫苗。后来向完全接种CoronaVac的人提供了使用BNT 162 b2或CoronaVac获得第三次加强剂量的选择。这三种疫苗以及CoronaVac疫苗接种后的加强剂的同时和比较性真实世界抗体数据很少。我们的研究旨在评估这些疫苗接种方案后的抗体应答。我们进行了一项前瞻性、纵向的基于人群的研究，以测量SARS-CoV-2抗刺突受体结合域（RBD）IgG浓度，通过分析采集的血液样本进行评估，在北塞浦路斯的参与者中，他们在第二次接种后1个月和3个月接受了BNT 162 b2、ChAdOx 1或CoronaVac疫苗。参与者在接种疫苗后自愿来到实验室进行检测时被招募，从卫生保健接入点或普通人群中招募。我们还评估了在初级CoronaVac方案后加强剂量的BNT 162 b2或CoronaVac后1个月的抗体应答。通过电话访谈或直接从实验室收集人口统计学、基线特征、疫苗接种反应和抗体应答者百分比，并按疫苗和年龄组进行总结。通过参数和非参数方法比较组间抗体水平随时间的变化。招募、随访和数据收集于2021年3月1日至9月30日期间完成。BNT 162 b2诱导最高的血清阳性率和抗尖峰RBD IgG抗体滴度，其次是ChAdOx 1，然后是CoronaVac。此外，CoronaVac的抗体下降速度最快，其次是ChAdOx 1，然后是BNT 162 b2。对于老年组，第二次给药后3个月的血清阳性率为：BNT 162 b2 100%，ChAdOx 1 90%，CoronaVac 60%。在多变量重复测量模型中，较低的抗体滴度也与男性性别、年龄较大和接种疫苗后的时间显著相关。与用CoronaVac加强相比，在6个月时用单次BNT 162 b2剂量加强两次剂量CoronaVac方案导致IgG滴度显著增加;对于60岁及以上年龄组，加强免疫后抗体滴度相对于基线后1个月的几何平均倍数增加为7.9（95% CI 5.8 - 10.8）对比CoronaVac组中的2.8（1.6 - 5.0）。这些纵向数据可以帮助制定疫苗接种策略。鉴于60岁或以上人群中CoronaVac组的抗体滴度较低且快速下降，可以考虑将更有效的疫苗选择作为这些高风险人群的初次接种或加强剂量，以维持更长时间的抗体应答。在北塞浦路斯众筹。
Vaccination is an efficient strategy to control the COVID-19 pandemic. In north Cyprus, vaccine distribution started with CoronaVac followed by BNT162b2, and ChAdOx1 vaccines. An option to obtain a third booster dose with BNT162b2 or CoronaVac was later offered to people fully inoculated with CoronaVac. There are few simultaneous and comparative real-world antibody data for these three vaccines as well as boosters after CoronaVac vaccination. Our study was aimed at evaluating antibody responses after these vaccination schemes. We did a prospective, longitudinal population-based study to measure SARS-CoV-2 anti-spike receptor binding domain (RBD) IgG concentrations, assessed by assaying blood samples collected, in participants in north Cyprus who had received the BNT162b2, ChAdOx1, or CoronaVac vaccine at 1 month and 3 months after the second dose. Participants were recruited when they voluntarily came to the laboratory for testing after vaccination, solicited from health-care access points, or from the general population. We also evaluated antibody responses 1 month after a booster dose of BNT162b2 or CoronaVac after primary CoronaVac regimen. Demographics, baseline characteristics, vaccination reactions, and percentage of antibody responders were collected by phone interviews or directly from the laboratory summarised by vaccine and age group. Antibody levels were compared between groups over time by parametric and non-parametric methods. Recruitment, follow-up, and data collection was done between March 1 and Sept 30, 2021. BNT162b2 induced the highest seropositivity and anti-spike RBD IgG antibody titres, followed by ChAdOx1, and then by CoronaVac. In addition, the rate of decline of antibodies was fastest with CoronaVac, followed by ChAdOx1, and then by BNT162b2. For the older age group, the rate of seropositivity at 3 months after the second dose was 100% for BNT162b2, 90% for ChAdOx1, and 60% for CoronaVac. In the multivariate repeated measures model, lower antibody titres were also significantly associated with male sex, older age, and time since vaccination. Boosting a two-dose CoronaVac regimen at 6 months with a single BNT162b2 dose led to significantly increased titres of IgG compared with boosting with CoronaVac; for the 60 years and older age group, the geometric mean fold rise in antibody titre after the booster relative to 1 month post-baseline was 7·9 (95% CI 5·8–10·8) in the BNT162b2 boost group versus 2·8 (1·6–5·0) in the CoronaVac group. These longitudinal data can help shape vaccination strategies. Given the low antibody titres and fast decline in the CoronaVac group in individuals 60 years or older, more potent vaccine options could be considered as the primary vaccination or booster dose in these high-risk populations to sustain antibody responses for longer. Crowdfunded in north Cyprus.
影响因子：
5.2
作者：
Barin B;Yoldascan BE;Savaskan F;Ozbalikci G;Karaderi T;Çakal H
通讯作者：
Çakal H